Shkreli's Price-Hike Brag: '$1bn Here We Come'
This article was originally published in Scrip
Executive Summary
Excerpts from more than 300,000 documents, including emails, from Turing Pharmaceuticals Inc. and Valeant Pharmaceuticals International Inc. painted a picture that's anything but pretty about how those firms went about buying older drugs and jacking up their prices – with the now-former head of one of those companies, Martin Shkreli, declaring "$1bn here we come."
You may also be interested in...
FDA Approves First Generic Of Daraprim
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.